NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

AgomAb Therapeutics AGMB

AgomAb Therapeutics listed on Nasdaq on 6 Feb 2026 and is not in the S&P 500. It is worth $192 million. 8 directors have filed with the SEC in the last 12 months (who counts), 1 of them an executive. 5 other officers are on file. At 30 Jun 2026, Eqt Fund Management S.a r.l. was its largest institutional holder, with 15.1% of the company.

CEO
Tim Jasper Knotnerus
Listed
6 Feb 2026 on Nasdaq, IPO filings and terms
Headquarters
Antwerpen, Belgium
Market cap
$192M
19 Nov 2026 close
Revenue
-
No annual report yet

Board and leadership

Board and officers

Roles filed up to 30 Sep 2026

NameTitle
Directors (8)
Tim Jasper KnotnerusChief Executive OfficerLast filed 18 Mar 2026Chief Executive Officer
Colin Michael BondDirectorLast filed 18 Mar 2026Director
David R. EpsteinDirectorLast filed 18 Mar 2026Director
Marino GarciaDirectorDirector
Ohad HammerDirectorLast filed 18 Mar 2026Director
Angelika Martha JahreisDirectorLast filed 18 Mar 2026Director
Naimish PatelDirectorDirector
Felice Isabel Verduyn-van WeegenDirectorLast filed 18 Mar 2026Director
Officers (5)
Pierre Thadee Victor KemulaChief Financial OfficerLast filed 18 Mar 2026Chief Financial Officer
Andrea Saez BorderiasChief Development OfficerLast filed 18 Mar 2026Chief Development Officer
Paul Henryk van der HorstChief Business OfficerLast filed 18 Mar 2026Chief Business Officer
Ellen LefeverGeneral CounselLast filed 18 Mar 2026General Counsel
Philippe Constantin WieselChief Medical OfficerLast filed 18 Mar 2026Chief Medical Officer

Owners and trading

Largest institutional holders

Each fund group's share of AgomAb Therapeutics. Where a company has several share classes, the share is of its total value.

13F filings for the quarter to 30 Jun 2026

  • Eqt Fund Management S.a r.l.15.1%
  • Sanofi8.2%
  • Redmile Group8.0%
  • Cormorant Asset Management7.2%
  • Tcg Crossover Management6.0%

These five hold 44.4% of AgomAb Therapeutics.

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers made no open-market sales and bought $619,999 in 10 purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
17 Nov 2026BuyDavid R. EpsteinDirectorDirectorBuy5,000$28K
13 Nov 2026BuyDavid R. EpsteinDirectorDirectorBuy14,980$89K
5 Nov 2026BuyDavid R. EpsteinDirectorDirectorBuy15,000$104K
21 Oct 2026BuyDavid R. EpsteinDirectorDirectorBuy10,000$89K
8 Oct 2026BuyDavid R. EpsteinDirectorDirectorBuy5,000$45K
6 Oct 2026BuyPierre Thadee Victor KemulaChief Financial OfficerChief Financial OfficerBuy10,000$86K
6 Oct 2026BuyDavid R. EpsteinDirectorDirectorBuy5,000$44K
6 Oct 2026BuyTim Jasper KnotnerusChief Executive OfficerChief Executive OfficerBuy5,000$44K
5 Oct 2026BuyTim Jasper KnotnerusChief Executive OfficerChief Executive OfficerBuy6,000$51K
5 Oct 2026BuyDavid R. EpsteinDirectorDirectorBuy5,000$43K

Not on file: no weekly market cap history, no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months, no quarterly results in its SEC XBRL filings and no director or officer changes, WARN notices or large insider sales in the last two years.